← Oncology Approval Tracker

FDA DECISION ·

Tecartus

brexucabtagene autoleucel · Kite Pharma

Traditional approvalTraditional conversionMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory mantle cell lymphoma. FDA converted the accelerated indication to traditional approval.

LAMPGEN ANALYSIS

Why it matters

This completes the accelerated-approval pathway for the mantle cell lymphoma use of Tecartus. The decision is specific to that CAR-T indication.

What research teams should watch

Keep MCL evidence separate from the product’s other uses. Verify follow-up obligations, referral timelines and the practical constraints of CAR-T delivery.

PRIMARY RECORDS

Sources